JP2013541330A5 - - Google Patents

Download PDF

Info

Publication number
JP2013541330A5
JP2013541330A5 JP2013528336A JP2013528336A JP2013541330A5 JP 2013541330 A5 JP2013541330 A5 JP 2013541330A5 JP 2013528336 A JP2013528336 A JP 2013528336A JP 2013528336 A JP2013528336 A JP 2013528336A JP 2013541330 A5 JP2013541330 A5 JP 2013541330A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013528336A
Other languages
English (en)
Japanese (ja)
Other versions
JP5866130B2 (ja
JP2013541330A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051035 external-priority patent/WO2012034039A2/en
Publication of JP2013541330A publication Critical patent/JP2013541330A/ja
Publication of JP2013541330A5 publication Critical patent/JP2013541330A5/ja
Application granted granted Critical
Publication of JP5866130B2 publication Critical patent/JP5866130B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013528336A 2010-09-10 2011-09-09 抗IL−1β抗体およびその使用方法 Expired - Fee Related JP5866130B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38188310P 2010-09-10 2010-09-10
US61/381,883 2010-09-10
PCT/US2011/051035 WO2012034039A2 (en) 2010-09-10 2011-09-09 Anti-il-1 beta antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2013541330A JP2013541330A (ja) 2013-11-14
JP2013541330A5 true JP2013541330A5 (enExample) 2014-09-11
JP5866130B2 JP5866130B2 (ja) 2016-02-17

Family

ID=45811182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013528336A Expired - Fee Related JP5866130B2 (ja) 2010-09-10 2011-09-09 抗IL−1β抗体およびその使用方法

Country Status (8)

Country Link
US (1) US9085621B2 (enExample)
EP (1) EP2614085B1 (enExample)
JP (1) JP5866130B2 (enExample)
CN (1) CN103328511B (enExample)
AU (1) AU2011299066A1 (enExample)
NZ (1) NZ607510A (enExample)
RU (1) RU2013115927A (enExample)
WO (1) WO2012034039A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
AU2011268229B2 (en) 2010-06-18 2015-04-16 Xbiotech Inc. Arthritis treatment
ES2622482T3 (es) 2010-08-23 2017-07-06 Xbiotech, Inc Tratamiento de enfermedades neoplásicas
JP5866130B2 (ja) 2010-09-10 2016-02-17 アペクシジェン, インコーポレイテッド 抗IL−1β抗体およびその使用方法
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
KR20190090046A (ko) * 2011-04-01 2019-07-31 엑스바이오테크, 인크. 피부과학적 병리의 치료
WO2013139701A1 (en) * 2012-03-19 2013-09-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment or the prevention of aneurysm
JP6333271B2 (ja) 2012-11-05 2018-06-06 セル メディカ スイッツァランド アーゲー IL−1βへの結合メンバー
ES2895848T3 (es) 2012-12-17 2022-02-22 Cell Medica Inc Anticuerpos contra IL-1 beta
FR3003172B1 (fr) * 2013-03-15 2017-12-08 Lab Francais Du Fractionnement Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
RU2017120360A (ru) 2014-11-10 2018-12-13 Ф.Хоффманн-Ля Рош Аг Биспецифические антитела и способы их применения в офтальмологии
AU2015345320A1 (en) * 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
JP2017534644A (ja) 2014-11-10 2017-11-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗ang2抗体及び使用方法
JP2020506971A (ja) 2017-02-08 2020-03-05 ドラゴンフライ セラピューティクス, インコーポレイテッド ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
SG11201907159SA (en) 2017-02-16 2019-09-27 Xbiotech Inc Treatment of hidradenitis suppurativa
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
FI3749346T3 (fi) 2018-02-08 2024-09-04 Dragonfly Therapeutics Inc Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
MX2020008684A (es) 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16及び腫瘍関連抗原に結合するタンパク質
US12384851B2 (en) 2018-08-08 2025-08-12 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
EP3878867A4 (en) * 2018-11-07 2022-07-06 Zeda Biopharmaceuticals, Inc. Antibody binding to human il-1 ?, preparation method therefor and use thereof
MX2021007488A (es) * 2018-12-21 2021-08-05 Novartis Ag Uso de anticuerpos il-1 beta en el tratamiento o prevencion del sindrome mielodisplasico.
US20220356240A1 (en) * 2019-09-26 2022-11-10 Beth Israel Deaconess Medical Center, Inc. Anti-inflammatory therapy in arrhythmogenic cardiomyopathy (acm)
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合nkg2d、cd16及clec12a之蛋白質
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004016740A2 (en) * 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CN1780855B (zh) * 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
CA2533830A1 (en) * 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
EP2361933A3 (en) * 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
US7429487B2 (en) * 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
KR102824865B1 (ko) 2007-05-29 2025-06-26 노파르티스 아게 항-il-1-베타 치료법에 대한 신규 적응증
PT2293816E (pt) 2008-06-06 2013-02-13 Xoma Technology Ltd Métodos para o tratamento da artrite reumatoide
EP2341936A4 (en) 2008-09-05 2012-07-25 Xoma Technology Ltd METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
JP5866130B2 (ja) 2010-09-10 2016-02-17 アペクシジェン, インコーポレイテッド 抗IL−1β抗体およびその使用方法

Similar Documents

Publication Publication Date Title
JP5866130B2 (ja) 抗IL−1β抗体およびその使用方法
JP7482184B2 (ja) 抗cd40抗体および使用方法
JP6097702B2 (ja) 抗il−6受容体抗体およびその使用方法
JP6807890B2 (ja) 抗cd40抗体および使用方法
JP2013541330A5 (enExample)
JP2014515612A5 (enExample)
US20190309080A1 (en) Anti-rankl antibodies and methods of use
US20190218296A1 (en) Anti-pd-l1 antibodies and methods of use
HK40068031A (en) Anti-cd40 antibodies and methods of use
HK40011413A (en) Anti-cd40 antibodies and methods of use
HK1240603B (zh) 抗-cd40抗体及其使用方法
HK1187059B (en) Anti-il-1 beta antibodies and methods of use